While an upfront perk can be compelling, remember to look beyond headline figures
Co-administration leads to greater reductions in albuminuria and more pronounced initial declines in eGFR, indicative of reduced intraglomerular pressure [122,123]
When prescribed by a licensed provider, these treatments may help patients reduce caloric intake and support progress toward individualized weight management goals as part of a broader care plan
"GLP-1 coverage" on a benefits summary may or may not include the Wegovy brand
Step 4: Schedule a check-in with your PlexusDx provider to discuss dose adjustment or, if appropriate, genetic testing through the Precision Peptide Genetic Test
This practice is not approved by the FDA, and the medication's manufacturer, Novo Nordisk, only recommends once-weekly dosing